Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03838042
Recruitment Status : Recruiting
First Posted : February 12, 2019
Last Update Posted : October 15, 2019
Sponsor:
Collaborator:
German Cancer Research Center
Information provided by (Responsible Party):
Prof. Dr. Olaf Witt, University Hospital Heidelberg

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : March 2023